SOURCE: Wake Pharma US

Wake Pharma US

October 21, 2009 00:01 ET

Wake Pharma US Unveils Five New Posters at Clinical Symposium on Advances in Skin & Wound Care

ELK GROVE VILLAGE, IL--(Marketwire - October 21, 2009) - Wake Pharma US has been selected to participate in the Clinical Symposium on Advances in Skin and Wound Care: Conference for Prevention and Healing in San Antonio, Texas October 22-25, 2009. Wake Pharma US will present five exciting new posters detailing the clinical treatment of wounds using Wound-Be-Gone®. The symposium will be held at the Grand Hyatt and Gonzales Convention Center in San Antonio. The clinical evidence and data will be presented through posters on display during the meeting.

The first new poster, At Home Or In A Hospital: A Simple, Yet Effective OTC Wound Gel That Makes A Wound "Be Gone", highlights the clinical and economic challenges most physicians face when treating acute and chronic wounds. Using Wound-Be-Gone®, clinicians were able to accelerate healing and simplify treatment in a series of 5 patients with minimal cost.

The second poster, A Novel Approach To Moist Wound Healing Using A Hydrophilic Gel With Free Radical Binding Properties, presents clinical data collected for patients over 60 days where the moist healing and Free Radical Binding technologies found in Wound-Be-Gone®, produced uncomplicated wound healing and re-epithelialization.

The third poster, Novel Hydrophilic Gel (Wound-Be-Gone®)) Enhances Healing Via Oxygen Free Radical Binding Technology, examines a series of patients with compromised lower extremity wounds who were managed with a hydrophilic gel (Wound-Be-Gone®) and achieved positive wound healing trajectories as evidenced by robust granulation tissue development and rapid epithelialization.

The fourth new poster, Wound Healing By Binding Reactive Oxygen Species (ROS), details a series of diabetic patients who were randomized to topical therapy of either hydrogel (control) or an ROS antagonist polymer (Wound-Be-Gone®). Compared to controls hydrophilic gel, treatment using the ROS antagonist polymer demonstrated rapid healing and decreased inflammation.

The final poster, Enhanced Cosmetic Results In African American Skin Pigmentation Using A Polymer Hydrogel With Oxygen Free Radical Binding Technology, will detail four African American patients who used Wound-Be-Gone® and achieved incredible results without the typical de-pigmentation associated with wound healing in African Americans. This de-pigmentation is a common cosmetic side effect of traditional wound healing therapies, and has been shown to produce physical and psychological complications in patients.

For more information on these or other clinical posters, as well as clinical case studies, please visit: www.woundbegone.com

Wake Pharma US, Inc encourages the adoption of cost-effective strategies and approaches for acute and chronic wound management.

Wound-Be-Gone® is a novel product based on revolutionary technology in the healing of wounds. Based on a unique and patented principle, it is vastly different from current healing products on the market. It has a wide range of uses with a minimal side effect profile; and minimal contraindications. It contains no antibiotics or material of biological origin.

About Wake Pharma US, Inc.

Wake Pharma US, Inc. is an innovative and international company with its own manufacturing facility located in the European Union. Wake Pharma US, Inc. specializes in development, marketing and distribution of revolutionary and unique products to the health marketplace.

Contact Information